<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209050</url>
  </required_header>
  <id_info>
    <org_study_id>BVT.Surfacer.17-01</org_study_id>
    <nct_id>NCT03209050</nct_id>
  </id_info>
  <brief_title>Evaluation of the Surfacer System Approach to Central Venous Access</brief_title>
  <acronym>SAVEUS</acronym>
  <official_title>Evaluation of the Surfacer System Approach to Central Venous Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bluegrass Vascular Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bluegrass Vascular Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-market Investigational device exemption study evaluating the safety and efficacy of the&#xD;
      Surfacer System to facilitate stable upper body central venous access suitable for any&#xD;
      conventional catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single arm, multi-center study is to demonstrate the safety and efficacy of&#xD;
      the Surfacer System. Safety will be evaluated based on the overall rate of acute&#xD;
      complications using the study device as compared to historical rates of device/procedure&#xD;
      related safety events using conventional central venous access methods. Efficacy will be&#xD;
      evaluated by the rate of transient successful central venous accesses created by the study&#xD;
      device. A total of 30 patients are planned to be enrolled, with 10 patients initially&#xD;
      following review of safety data. Duration expected to be through 7 days. A minimum of 3 sites&#xD;
      will participate in the study in the United States.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>patients requiring venous access</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Safe Insertion and Patency of Central Venous Access Catheter</measure>
    <time_frame>7 days</time_frame>
    <description>Safety reported as 86.7% (26/30) % of subjects with no procedural complications at discharge through 7 days follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Safe Use of the System to Insert Femoral Vein to Sub-clavicular Exit as Assessed by Central Venous Access Placement in 30 Patients Attempted</measure>
    <time_frame>7 days</time_frame>
    <description>Safety and Efficacy 90.0% (27/30) successful central venous catheter placements as assessed by patent open central venous access catheter. Ability to use the central venous access catheter for dialysis and infusion through 7 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Venous Occlusion</condition>
  <arm_group>
    <arm_group_label>Central Venous Access Placement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Central venous access placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Central Venous Access Placement</intervention_name>
    <description>Device inserted into the femoral vein to insert a central venous access catheter</description>
    <arm_group_label>Central Venous Access Placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  referred for placement of central venous access catheter&#xD;
&#xD;
          -  have limited or diminishing upper body venous access&#xD;
&#xD;
          -  have pathology impeding standard access methods&#xD;
&#xD;
          -  willing to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  occlusion of the right femoral vein&#xD;
&#xD;
          -  occlusion of the iliac vein&#xD;
&#xD;
          -  occlusion of the inferior vena cava&#xD;
&#xD;
          -  contraindicated by physician&#xD;
&#xD;
          -  acute thrombosis within any vessel planned to be crossed by the Surfacer *tortuous&#xD;
             anatomy which precludes a straight line from femoral vein to subclavian&#xD;
&#xD;
          -  diagnosed with active pericarditis&#xD;
&#xD;
          -  diagnosed with active endocarditis&#xD;
&#xD;
          -  suspected pericardial effusion&#xD;
&#xD;
          -  known or suspected aneurysm or ectasia of ascending aorta&#xD;
&#xD;
          -  innominate artery or subclavian artery&#xD;
&#xD;
          -  pregnant or of childbearing potential not taking adequate contraceptive measures or&#xD;
             nursing during study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Tocchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meditrial Europe Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <results_first_submitted>July 30, 2020</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2021</results_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03209050/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Central Venous Access Placement</title>
          <description>Central venous access placement&#xD;
Central Venous Access Placement: Device inserted into the femoral vein to insert a central venous access catheter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patients with central venous disease with pathology impeding standard access methods</population>
      <group_list>
        <group group_id="B1">
          <title>Central Venous Access Placement</title>
          <description>Central venous access placement&#xD;
Central Venous Access Placement: Device inserted into the femoral vein to insert a central venous access catheter</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>chronic Kidney disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Safe Insertion and Patency of Central Venous Access Catheter</title>
        <description>Safety reported as 86.7% (26/30) % of subjects with no procedural complications at discharge through 7 days follow up.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Central Venous Access Placement</title>
            <description>Central venous access placement in 26/30 patients&#xD;
Central Venous Access Placement: Device inserted into the femoral vein to insert a central venous access catheter in 26/30 patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Safe Insertion and Patency of Central Venous Access Catheter</title>
          <description>Safety reported as 86.7% (26/30) % of subjects with no procedural complications at discharge through 7 days follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Clopper-Pearson 95% CI</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Safe Use of the System to Insert Femoral Vein to Sub-clavicular Exit as Assessed by Central Venous Access Placement in 30 Patients Attempted</title>
        <description>Safety and Efficacy 90.0% (27/30) successful central venous catheter placements as assessed by patent open central venous access catheter. Ability to use the central venous access catheter for dialysis and infusion through 7 days</description>
        <time_frame>7 days</time_frame>
        <population>patients treated with central venous access device</population>
        <group_list>
          <group group_id="O1">
            <title>Central Venous Access Placement</title>
            <description>Central venous access placement in 27/30 patients&#xD;
Central Venous Access Placement: Device inserted into the femoral vein to insert a central venous access catheter in 27/30 patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Safe Use of the System to Insert Femoral Vein to Sub-clavicular Exit as Assessed by Central Venous Access Placement in 30 Patients Attempted</title>
          <description>Safety and Efficacy 90.0% (27/30) successful central venous catheter placements as assessed by patent open central venous access catheter. Ability to use the central venous access catheter for dialysis and infusion through 7 days</description>
          <population>patients treated with central venous access device</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks or 30 days</time_frame>
      <desc>Overall number of participants who experienced adverse events as a result of the access procedure per definitions within 24 hours of occurrence.</desc>
      <group_list>
        <group group_id="E1">
          <title>Central Venous Access Placement</title>
          <description>Central venous access placement&#xD;
Central Venous Access Placement: Device inserted into the femoral vein to insert a central venous access catheter</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>bleeding</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Hypotension">Hypotension</sub_title>
                <description>Hypovolemia causing Hypotension post dialysis, resolved with inpatient hospitalization greater than 24 hours</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Bleeding requiring transfusion and narcan and colloidal solution. In patient hospitalization greater than 24 hours</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="hemodynamic unstable">Hemodynamic Instability</sub_title>
                <description>low blood pressure requiring vasopressors, extended hospitalization greater than 24 hours</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="embolization">unintended embolization</sub_title>
                <description>anticoagulants administered, in patient hospitalization greater than 24 hours</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>bleeding</sub_title>
                <description>bleeding at the central venous access site, resolved with transfusion</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>allergic reaction</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>allergic reaction</sub_title>
                <description>one allergic reaction occurred rated as mild adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Organization and Trial Manager</name_or_title>
      <organization>mmc medical international services</organization>
      <phone>9492805700</phone>
      <email>laura22@mmc-medical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

